Adrenal hormone synthesis inhibitors

Adrenal hormone synthesis inhibitors

Internal Medicine

Internal Medicine

Blood transfusion reactions and transplant rejection: Pathology review
Immunodeficiencies: Clinical
Antihistamines for allergies
Glucocorticoids
Non-corticosteroid immunosuppressants and immunotherapies
Advanced cardiac life support (ACLS): Clinical
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Heart blocks: Pathology review
Coronary artery disease: Clinical
Heart failure: Clinical
Syncope: Clinical
Pericardial disease: Clinical
Cardiomyopathies: Clinical
Hypertension: Clinical
Hypercholesterolemia: Clinical
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Sympathomimetics: Direct agonists
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Diabetes mellitus: Clinical
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Parathyroid conditions and calcium imbalance: Clinical
Pituitary adenomas and pituitary hyperfunction: Clinical
Hypopituitarism: Clinical
Cushing syndrome: Clinical
Adrenal masses and tumors: Clinical
Adrenal insufficiency: Clinical
MEN syndromes: Clinical
Neuroendocrine tumors of the gastrointestinal system: Pathology review
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Esophageal disorders: Clinical
Esophagitis: Clinical
Gastroesophageal reflux disease (GERD): Clinical
Gastroparesis: Clinical
Malabsorption: Clinical
Inflammatory bowel disease: Clinical
Jaundice: Clinical
Cirrhosis: Clinical
Laxatives and cathartics
Antidiarrheals
Acid reducing medications
Fever of unknown origin: Clinical
Fat-soluble vitamin deficiency and toxicity: Pathology review
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Anemia: Clinical
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Leukemia: Clinical
Lymphoma: Clinical
Thrombocytopenia: Clinical
Bleeding disorders: Clinical
Thrombophilia: Clinical
Myeloproliferative neoplasms: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Infective endocarditis: Clinical
Pneumonia: Clinical
Tuberculosis: Pathology review
Diarrhea: Clinical
Viral hepatitis: Clinical
Urinary tract infections: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Bites and stings: Clinical
HIV and AIDS: Pathology review
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory acidosis: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Nephritic and nephrotic syndromes: Clinical
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Environmental and chemical toxicities: Pathology review
Osmotic diuretics
Carbonic anhydrase inhibitors
Loop diuretics
Potassium sparing diuretics
Stroke: Clinical
Seizures: Clinical
Headaches: Clinical
Dementia and delirium: Clinical
Hyperkinetic movement disorders: Clinical
Hypokinetic movement disorders: Clinical
Muscle weakness: Clinical
Disorders of consciousness: Clinical
Spinal cord disorders: Pathology review
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Migraine medications
Anti-parkinson medications
Medications for neurodegenerative diseases
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Diffuse parenchymal lung disease: Clinical
Venous thromboembolism: Clinical
Acute respiratory distress syndrome: Clinical
Pleural effusion: Clinical
Pneumothorax: Clinical
Lung cancer: Clinical
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Joint pain: Clinical
Rheumatoid arthritis: Clinical
Seronegative arthritis: Clinical
Systemic lupus erythematosus (SLE): Clinical
Sjogren syndrome: Clinical
Inflammatory myopathies: Clinical
Vasculitis: Clinical
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Antigout medications
Non-biologic disease modifying anti-rheumatic drugs (DMARDs)
Osteoporosis medications

Transcript

Watch video only

Adrenal hormone synthesis inhibitors or AHSIs are a group of medications which basically inhibit the synthesis of adrenocortical hormones, more specifically cortisol, which is a glucocorticoid hormone produced by the adrenal cortex.

Normally, the hypothalamus, which is located at the base of the brain, secretes corticotropin-releasing hormone, known as CRH, which stimulates the pituitary gland to secrete adrenocorticotropic hormone, known as ACTH.

ACTH, then, travels to the pair of adrenal glands, on top of each kidney, where it specifically targets cells in the adrenal cortex.

This causes the adrenocortical cells to take up cholesterol from the blood, and it also stimulates an enzyme called cholesterol desmolase inside these cells, which converts cholesterol to pregnenolone.

Then, another enzyme called 3 beta- hydroxysteroid dehydrogenase, (or 3 beta- HSD) turns some of this pregnenolone into progesterone.

Now, the synthesis of cortisol starts when pregnenolone and progesterone move into the zona fasciculata.

The enzyme 17 alpha-hydroxylase turns pregnenolone into 17 alpha- hydroxypregnenolone and turns progesterone into 17 alpha hydroxyprogesterone.

17 alpha hydroxypregnenolone is then turned into 17 alpha hydroxyprogesterone by the enzyme 3 beta- hydroxysteroid dehydrogenase.

Then, all of the 17 alpha hydroxyprogesterone is turned into 11 deoxycortisol by the enzyme 21 hydroxylase.

11 deoxycortisol is finally turned into cortisol by the enzyme 11 beta-hydroxylase.

Cortisol is also known as the stress hormone.

In times of stress, the body needs to have plenty of energy substrates around, so cortisol increases gluconeogenesis, which is the synthesis of new glucose molecules, proteolysis, which is the breakdown of protein and lipolysis, which is the breakdown of fat.

Cortisol also helps to maintain the blood pressure by increasing the sensitivity of peripheral blood vessels to catecholamines- epinephrine and norepinephrine, and this narrows the blood vessel lumen.

Cortisol helps to dampen the inflammatory and immune response by reducing the production and release of inflammatory mediators, like prostaglandins and interleukins, as well as inhibiting the proliferation of T-lymphocytes.

Finally, cortisol receptors are present in the brain, where their full effect is still actually unclear but might influence things like mood and memory.

Now, in Cushing’s syndrome, there’s increased cortisol levels over a long period of time.

This could be due to Cushing’s disease, which is caused by a benign pituitary adenoma that secretes too much ACTH.

Another cause is adrenocortical carcinomas, which overproduce cortisol.

Excess cortisol leads to severe muscle and skin breakdown which are the major protein stores in the body.

Bones are also broken down which could lead to osteoporosis.

It also elevates blood glucose levels, and that leads to high insulin levels.

Insulin, among its many actions, preferentially targets adipocytes or fat cells in the center of the body - around the waist and buttocks.

In those cells, the insulin activates lipoprotein lipase, which is an enzyme that helps those adipocytes accumulate more fat molecules.

The result is central obesity, which is fat build up in the abdomen, buffalo hump, which is fat build up between the shoulders, and moon facies which is fat build up in the face.

Excess cortisol also dampens the inflammatory and immune response, making individuals more susceptible to infections.

Alright, so, whatever the cause, the problem is high cortisol level.

So, to solve all these problems, we have to decrease the level of cortisol in the body.

We can do this by inhibiting the synthesis of cortisol with the help of adrenal hormone synthesis inhibitors, or AHSIs, like ketoconazole, metyraPONE aminoglutethimide and etomidate.

If these medications fail, we can also destroy the adrenocortical cells with mitotane.

Let’s begin with Ketoconazole, which is an antifungal medication that is also used as the first-line treatment for Cushing’s syndrome.

It’s taken orally and it works by inhibiting several enzymes important in the synthesis of adrenal steroids.

First, it inhibits the enzyme called cholesterol desmolase; thereby preventing the conversion of cholesterol to pregnenolone.

This way ketoconazole decreases the synthesis of all adrenal hormones!

Next, ketoconazole inhibits the enzyme 17α-hydroxylase, thereby blocking the conversion of pregnenolone to 17-hydroxypregnenolone; and conversion of progesterone to 17-hydroxyprogesterone.

Ultimately, this results in decreased synthesis of cortisol!

Finally, ketoconazole inhibits the enzyme 17, 20-lyase, eventually decreasing the synthesis of androgens!

The antiandrogenic effect is particularly useful for adrenocortical carcinomas which are associated with increased production of all adrenocortical hormones like cortisol and androgens.

Other indications for ketoconazole include breast and prostate cancer; but it’s important to note that it can be also used to reduce androgenic symptoms, such as hirsutism, or excessive facial hair growth, and acne, in individuals with polycystic ovary syndrome (PCOS).

The main side effects of ketoconazole include nausea, vomiting, hepatotoxicity, decreased libido, and sedation.

It’s also teratogenic so it should not be given during pregnancy.

Finally, it’s important to note that ketoconazole is a potent CYP3A4 inhibitor; therefore, concomitant use of ketoconazole and medications that are metabolized by this enzyme can lead to their decreased metabolism, increased blood levels, and eventual toxicity.

Key Takeaways

Adrenal hormone synthesis inhibitors are medicinal drugs that act to suppress the production of adrenal hormones. These drugs can be used to manage conditions where excess adrenal hormone production leads to symptoms such as Cushing's syndrome or Conn's syndrome. There are a variety of adrenal hormone synthesis inhibitors available, with different mechanisms of action and potencies. Some common examples include ketoconazole, metyrapone, and etomidate. Selection of the most appropriate drug depends on the individual patient's condition and other factors such as other medications being taken.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "The Treatment of Cushing's Disease" Endocrine Reviews (2015)
  5. "Preoperative treatment with metyrapone in patients with Cushing’s syndrome due to adrenal adenoma: a pilot prospective study" Endocrine Connections (2018)
  6. "Sex differences in ACTH pulsatility following metyrapone blockade in patients with major depression" Psychoneuroendocrinology (2007)
  7. "Medical management of Cushing’s disease: what is the future?" Pituitary (2012)